The Antibody Production Market is projected to reach $58.35 billion by 2030, at a CAGR of 11.4% from 2024–2031. Antibodies have therapeutics as well as diagnostic applications. Antibodies are majorly used for therapeutics for several diseases and conditions, such as cancer, autoimmune diseases, infectious diseases, and other conditions. The production of antibodies involves processes such as the downstream process and upstream process. Antibodies can be derived from sources such as mice and rabbit, among other sources.
The growth of this market is attributed to growing demand for targeted antibodies, increasing investments in R&D by pharma & biotech companies, growing prevalence of cancer and autoimmune diseases, increasing use of immunoassays, and advancements in bioprocessing technologies. However, the high cost of antibody production and stringent regulatory framework restrain the growth of this market.
Furthermore, growing applications of antibodies in clinical trials and medical research, significant opportunities from developing countries, and growing risk and prevalence of infectious diseases are expected to generate growth opportunities for the players operating in this market. However, the complex nature of monoclonal antibodies poses a challenge for market stakeholders during antibody production.
Antibodies are key to diagnosing and treating infectious diseases in the form of a detection or capture agent in an ELISA, a biomarker of interest, or a key vaccine component. The normal immune response to a viral or a microbial infection is the production of antibodies towards the antigens of the infection. Passive immunization for post-exposure prophylaxis or adjunct therapy has been successfully used for over a century to treat suspected exposure or infection against a range of diseases, such as rabies, diphtheria, tetanus, and hepatitis B. For most of these diseases, the immunoglobulin preparations administered to patients have been derived from immunized horses, immunized humans, and in some cases, from convalescent patients. Moreover, immunization with monoclonal antibodies has some advantages over active immunization with vaccines, such as protection afforded via passive immunization is immediate, and such protection can be induced in immunosuppressed individuals who are often at the highest risk of infection.
The growing prevalence and increasing risk of outbreaks of infectious diseases is expected to drive the adoption of antibodies for immunization, further leading to the demand for their production. According to an article published in the United Nations’ Africa Renewal digital magazine in July 2022, the risk of outbreaks caused by zoonotic pathogens such as the Ebola & monkeypox viruses that originate in animals and infect humans is rising. There has been a 63.0% increase in the number of zoonotic disease outbreaks in Africa from 2012–2022 compared to 2001– 2011.
Click here to: Get Free Sample Pages of this Report
Cancer poses a major burden on the global population and is further estimated to increase cancer cases, leading to mortality and degradation of quality of life. For instance, by 2030 the total number of new cancer cases is estimated to account for 24.6 million from 19.3 million in 2020 (Source: International Agency for Research on Cancer). Monoclonal antibodies (mABs) are used for the treatment of cancer as mABs are a type of targeted drug therapy. These drugs recognize and find specific proteins and cancer cells and help in the inhibition of their growth. Governments and several organizations and associations strive towards making better treatments and preventing cancer in people. Similarly, pharmaceutical & biopharmaceutical companies are developing newer drugs and biologics for the treatment of cancer. Pharma & biopharma companies are developing and gaining approvals for monoclonal antibodies for cancer. For instance, according to the Antibody Society, as of 2020, 43 monoclonal antibodies were approved or under review in the European Union or the U.S. Growing cancer prevalence and initiatives towards approval and development of mABs for cancer further lead to the increased production of antibodies.
Similarly, monoclonal antibodies are used to treat autoimmune diseases, a condition in which antibodies in an individual attack its own body, causing inflammation. Several anti-inflammatory monoclonal antibodies are used in the treatment of autoimmune diseases. For instance, monoclonal antibodies used to treat arthritis are known as tumor necrosis factor (TNF) inhibitors. TNF is a protein involved in causing inflammation and damage of rheumatoid arthritis. According to Lancet Diabetes & Endocrinology, in 2021, around 8.4 million people were affected with type-1 diabetes (one of the most common autoimmune diseases) globally. This number is estimated to increase to 13.5–17.4 million people by 2040. Also, as of 2022, around 1-1.5% of the European population (7 million) had celiac disease. (Source: European Parliament). Similarly, as of 2020, around 44 people per 100,000 population were affected with multiple sclerosis globally (Source: MS Atlas). The growing prevalence of autoimmune diseases is further expected to drive the demand for monoclonal antibodies for their treatment, driving the need for antibody production.
The instrument segment is further segmented into bioreactors, chromatography systems, filtration systems, and other instruments. Antibodies are widely used as diagnostic reagents and for therapeutic purposes, and their demand is increasing extensively. To produce these antibodies in sufficient quantities for commercial use, it is necessary to raise the output by scaling up the production processes. Bioreactors allow for better control of culture conditions, which can lead to higher cell densities and increased antibody yield. This can result in fewer runs needed to manufacture the desired amount of antibody, leading to the largest share of the segment. Furthermore, the chromatography systems are crucial in the quality control and filtration of the antibodies, leading to their high adoption.
The factors contributing to the segment’s large share are the wide array of applications of monoclonal antibodies in therapeutics for various diseases and conditions, the growing prevalence of chronic diseases, and the growing focus of pharm & biopharma companies on the development of monoclonal antibodies-based therapeutics.
Due to the availability, low cost, and quick production time for mouse mAbs, humanization of mouse mAbs has been implemented on a large scale. Furthermore, mouse husbandry is easier than rabbit husbandry, and the genetic approaches to engineering antibodies through recombinant technologies are more established for mice than other animals such rabbits, making mice a preferred choice for antibody production.
Downstream processing constitutes a critical step in manufacturing antibodies with regard to product purity, cost, and environmental impact. The purpose of downstream processing is to isolate, purify, and concentrate the previously synthesized antibody from the complex bulk matrix.
The large share of the segment is attributed to the growing R&D investments by pharma & biotech companies, increasing demand for biological therapeutics, high prevalence of chronic diseases, and capacity & geographic expansion of production facilities by the pharma & biopharma companies. Several pharma & biopharma are taking initiatives for the expansion of their production facilities, leading to the adoption of products for antibody production. For instance, in 2022, Seagen Inc. (U.S.), a biotechnology company focused on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer, announced the building of a new biologics facility. This facility will start its production in 2024 and will include monoclonal antibody production, fill & finish, quality control labs, package & labeling, warehouse, and office space.
In 2024, North America is expected to dominate the antibody production market, while Asia-Pacific is expected to record the highest CAGR during the forecast period. The high growth of the Asia-Pacific antibody production market is attributed to the growing pharmaceutical and biotech industry, supporting government initiatives, a large number of clinical trials conducted in the Asia-Pacific region, and growing demands and biologics for chronic & infectious diseases.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in this market in the last three to four years. The key players profiled in the antibody production market are Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KgaA (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Waters Corporation (U.S.), Shimadzu Corporation (Japan), Solaris Biotechnology Srl (Italy), and Infors AG (Switzerland).
|
Particular |
Details |
|
Page No |
~200 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
11.4% |
|
2030 Market Size (Value) |
$58.35 billion by 2031 |
|
Segments Covered |
By Product
By Antibody Type
By Source
By Process
By End User
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LATAM), Middle East & Africa |
|
Key Companies |
Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KgaA (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Waters Corporation (U.S.), Shimadzu Corporation (Japan), Solaris Biotechnology Srl (Italy), Infors AG (Switzerland) |
The antibody production market report covers market sizes & forecasts for instruments, consumables, and software. The antibody production market study includes the value analysis of various segments and subsegments of the antibody production market at the regional and country levels.
The antibody production market is projected to reach $58.35 billion by 2031, at a CAGR of 11.4% from 2024 to 2031.
The instruments segment is estimated to account for the largest share of the antibody production market in 2024. Moreover, this segment is expected to record the highest CAGR during the forecast period.
The monoclonal antibodies segment is projected to gain more traction in the antibody production market.
The high growth of the antibody production market is mainly attributed to the growing demand for targeted antibodies, increasing investments in R&D by pharma & biotech companies, the high burden and growing prevalence of cancer and autoimmune diseases, increasing use of immunoassays, and advancements in bioprocessing technologies.
Furthermore, growing applications of antibodies in clinical trials and medical research, significant opportunities from developing countries, and growing risk and prevalence of infectious diseases are expected to generate growth opportunities for the players operating in this market.
The key players operating in the antibody production market are Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KgaA (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Waters Corporation (U.S.), Shimadzu Corporation (Japan), Solaris Biotechnology Srl (Italy), Infors AG (Switzerland)
The emerging Asian-Pacific countries are expected to offer significant growth opportunities for the vendors in this market due to the growing pharmaceutical and biotech industry, supporting government initiatives, large number of clinical trials conducted in the Asia-Pacific region, and growing demands and biologics for chronic & infectious diseases.
This report provides pre & post COVID-19 market estimates.
1. Overview
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions For the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Drivers
4.2.1.1.1. Growing Demand for Targeted Antibodies
4.2.1.1.2. Increasing Investments In R&D By Pharma & Biotech Companies
4.2.1.1.3. High Burden and Growing Prevalence of Cancer and Autoimmune Diseases
4.2.1.1.4. Increasing Use of Immunoassays
4.2.1.1.5. Advancements In Bioprocessing Technologies
4.2.1.2. Restraints
4.2.1.2.1. High Cost of Antibody Production
4.2.1.2.2. Stringent Regulatory Frameworks
4.2.1.3. Opportunities
4.2.1.3.1. Growing Applications of Antibodies in Clinical Trials and Medical Research
4.2.1.3.2. Significant Opportunities from Developing Countries.
4.2.1.3.3. Growing Risk and Prevalence of Infectious Diseases
4.2.1.4. Challenges
4.2.1.4.1. Complex Nature of Monoclonal Antibodies
4.3. Regulatory Analysis
4.4. Porter’s Five Forces Analysis
4.5. Pricing Analysis
5. Antibody Production Market Assessment—by Product
5.1. Overview
5.2. Instruments
5.2.1. Bioreactors
5.2.1.1. Reusable Bioreactors
5.2.1.2. Single-use Bioreactors
5.2.2. Chromatography Systems
5.2.3. Filtration Systems
5.2.4. Other Instruments
5.3. Consumables
5.3.1. Cell Lines & Media
5.3.2. Buffers & Reagents
5.3.3. Chromatography Columns & Resins
5.3.4. Other Consumables
5.4. Software
6. Antibody Production Market Assessment—by Antibody Type
6.1. Overview
6.2. Monoclonal Antibodies
6.3. Polyclonal Antibodies
6.4. Recombinant Antibodies
7. Antibody Production Market Assessment—by Source
7.1. Overview
7.2. Mice
7.3. Rabbit
7.4. Other Sources
8. Antibody Production Market Assessment—by Process
8.1. Overview
8.2. Downstream
8.3. Upstream
9. Antibody Production Market Assessment—by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. CROs & CDMOs
9.4. Academic & Research Institutes
10. Antibody Production Market Assessment—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Ranking, by Key Players (2022)
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Thermo Fisher Scientific, Inc.
12.2. Merck KgaA
12.3. Eppendorf SE
12.4. Agilent Technologies, Inc.
12.5. Sartorius AG
12.6. Danaher Corporation
12.7. Waters Corporation
12.8. Shimadzu Corporation
12.9. Solaris Biotechnology Srl
12.10. Infors AG
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Global Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 2 Global Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 3 Global Antibody Production Instruments Market, By Country/Region, 2022–2031 (USD Million)
Table 4 Global Bioreactors Market for Antibody Production, By Type, 2022–2031 (USD Million)
Table 5 Global Bioreactors Market for Antibody Production, By Country/Region, 2022–2031 (USD Million)
Table 6 Global Reusable Bioreactors Market for Antibody Production, By Country/Region, 2022–2031 (USD Million)
Table 7 Global Single-use Bioreactors Market for Antibody Production, By Country/Region, 2022–2031 (USD Million)
Table 8 Global Filtration Systems Market for Antibody Production, By Country/Region, 2022–2031 (USD Million)
Table 9 Global Chromatography Systems Market for Antibody Production, By Country/Region, 2022–2031 (USD Million)
Table 10 Global Other Instruments Market for Antibody Production, By Country/Region, 2022–2031 (USD Million)
Table 11 Global Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 12 Global Antibody Production Consumables Market, By Country/Region, 2022–2031 (USD Million)
Table 13 Global Cell Lines & Media Market, By Country/Region, 2022–2031 (USD Million)
Table 14 Global Buffers & Reagents Market, By Country/Region, 2022–2031 (USD Million)
Table 15 Global Chromatography Columns & Resins Market, By Country/Region, 2022–2031 (USD Million)
Table 16 Global Other Antibody Production Consumables Market, By Country/Region, 2022–2031 (USD Million)
Table 17 Global Antibody Production Software Market, By Country/Region, 2022–2031 (USD Million)
Table 18 Global Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 19 Global Monoclonal Antibodies Production Market, By Country/Region, 2022–2031 (USD Million)
Table 20 Global Polyclonal Antibodies Production Market, By Country/Region, 2022–2031 (USD Million)
Table 21 Global Recombinant Antibodies Production Market, By Country/Region, 2022–2031 (USD Million)
Table 22 Global Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 23 Global Antibody Production Market for Mice, By Country/Region, 2022–2031 (USD Million)
Table 24 Global Antibody Production Market for Rabbit, By Country/Region, 2022–2031 (USD Million)
Table 25 Global Antibody Production Market for Other Sources, By Country/Region, 2022–2031 (USD Million)
Table 26 Global Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 27 Global Antibody Production Market for Downstream Process, By Country/Region, 2022–2031 (USD Million)
Table 28 Global Antibody Production Market for Upstream Process, By Country/Region, 2022–2031 (USD Million)
Table 29 Global Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 30 Global Antibody Production Market for Pharmaceutical & Biotechnology Companies, By Country/Region, 2022–2031 (USD Million)
Table 31 Global Antibody Production Market for CROs & CDMOs, By Country/Region, 2022–2031 (USD Million)
Table 32 Global Antibody Production Market for Academic & Research Institutes, By Country/Region, 2022–2031 (USD Million)
Table 33 Global Antibody Production Market, By Country/Region, 2022–2031 (USD Million)
Table 34 North America: Antibody Production Market, By Country, 2022–2031 (USD Million)
Table 35 North America: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 36 North America: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 37 North America: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 38 North America: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 39 North America: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 40 North America: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 41 North America: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 42 North America: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 43 U.S.: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 44 U.S.: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 45 U.S.: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 46 U.S.: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 47 U.S.: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 48 U.S.: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 49 U.S.: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 50 U.S.: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 51 Canada: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 52 Canada: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 53 Canada: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 54 Canada: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 55 Canada: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 56 Canada: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 57 Canada: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 58 Canada: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 59 Europe: Antibody Production Market, By Country, 2022–2031 (USD Million)
Table 60 Europe: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 61 Europe: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 62 Europe: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 63 Europe: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 64 Europe: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 65 Europe: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 66 Europe: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 67 Europe: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 68 Germany: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 69 Germany: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 70 Germany: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 71 Germany: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 72 Germany: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 73 Germany: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 74 Germany: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 75 Germany: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 76 France: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 77 France: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 78 France: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 79 France: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 80 France: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 81 France: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 82 France: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 83 France: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 84 U.K.: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 85 U.K.: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 86 U.K.: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 87 U.K.: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 88 U.K.: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 89 U.K.: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 90 U.K.: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 91 U.K.: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 92 Spain: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 93 Spain: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 94 Spain: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 95 Spain: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 96 Spain: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 97 Spain: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 98 Spain: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 99 Spain: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 100 Italy: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 101 Italy: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 102 Italy: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 103 Italy: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 104 Italy: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 105 Italy: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 106 Italy: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 107 Italy: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 108 RoE: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 109 RoE: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 110 RoE: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 111 RoE: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 112 RoE: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 113 RoE: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 114 RoE: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 115 RoE: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 116 Asia-Pacific: Antibody Production Market, By Country/Region, 2022–2031 (USD Million)
Table 117 Asia-Pacific: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 118 Asia-Pacific: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 119 Asia-Pacific: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 120 Asia-Pacific: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 121 Asia-Pacific: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 122 Asia-Pacific: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 123 Asia-Pacific: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 124 Asia-Pacific: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 125 China: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 126 China: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 127 China: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 128 China: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 129 China: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 130 China: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 131 China: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 132 China: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 133 Japan: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 134 Japan: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 135 Japan: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 136 Japan: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 137 Japan: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 138 Japan: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 139 Japan: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 140 Japan: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 141 RoAPAC: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 142 RoAPAC: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 143 RoAPAC: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 144 RoAPAC: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 145 RoAPAC: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 146 RoAPAC: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 147 RoAPAC: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 148 RoAPAC: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 149 Latin America: Antibody Production Market, By Country, 2022–2031 (USD Million)
Table 150 Latin America: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 151 Latin America: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 152 Latin America: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 153 Latin America: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 154 Latin America: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 155 Latin America: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 156 Latin America: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 157 Latin America: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 158 Brazil: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 159 Brazil: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 160 Brazil: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 161 Brazil: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 162 Brazil: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 163 Brazil: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 164 Brazil: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 165 Brazil: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 166 Mexico: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 167 Mexico: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 168 Mexico: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 169 Mexico: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 170 Mexico: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 171 Mexico: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 172 Mexico: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 173 Mexico: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 174 RoLATAM: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 175 RoLATAM: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 176 RoLATAM: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 177 RoLATAM: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 178 RoLATAM: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 179 RoLATAM: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 180 RoLATAM: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 181 RoLATAM: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 182 Middle East & Africa: Antibody Production Market, By Product, 2022–2031 (USD Million)
Table 183 Middle East & Africa: Antibody Production Instruments Market, By Type, 2022–2031 (USD Million)
Table 184 Middle East & Africa: Bioreactors for Antibody Production Market, By Type, 2022–2031 (USD Million)
Table 185 Middle East & Africa: Antibody Production Consumables Market, By Type, 2022–2031 (USD Million)
Table 186 Middle East & Africa: Antibody Production Market, By Antibody Type, 2022–2031 (USD Million)
Table 187 Middle East & Africa: Antibody Production Market, By Source, 2022–2031 (USD Million)
Table 188 Middle East & Africa: Antibody Production Market, By Process, 2022–2031 (USD Million)
Table 189 Middle East & Africa: Antibody Production Market, By End User, 2022–2031 (USD Million)
Table 190 Recent Developments, By Company, 2020-2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Antibody Production Market, By Product, 2024 Vs. 2031 (USD Million)
Figure 8 Global Antibody Production Market, By Antibody Type, 2024 Vs. 2031 (USD Million)
Figure 9 Global Antibody Production Market, By Source, 2024 Vs. 2031 (USD Million)
Figure 10 Global Antibody Production Market, By Process, 2024 Vs. 2031 (USD Million)
Figure 11 Global Antibody Production Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 12 Global Antibody Production Market, By Geography
Figure 13 Impact Analysis of Market Dynamics
Figure 14 Global Antibody Production Market, By Product, 2024 Vs. 2031 (USD Million)
Figure 15 Global Antibody Production Market, By Antibody Type, 2024 Vs. 2031 (USD Million)
Figure 16 Global Antibody Production Market, By Source, 2024 Vs. 2031 (USD Million)
Figure 17 Global Antibody Production Market, By Process, 2024 Vs. 2031 (USD Million)
Figure 18 Global Antibody Production Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 19 Global Antibody Production Market, By Geography, 2024 Vs. 2031 (USD Million)
Figure 20 North America: Antibody Production Market Snapshot
Figure 21 Europe: Antibody Production Market Snapshot
Figure 22 Asia-Pacific: Antibody Production Market Snapshot
Figure 23 Latin America: Antibody Production Market Snapshot
Figure 24 Key Growth Strategies Adopted by Leading Players (2021–2024)
Figure 25 Antibody Production Market: Competitive Benchmarking, By Product
Figure 26 Antibody Production Market: Competitive Benchmarking, By Region
Figure 27 Competitive Dashboard Antibody Production Market
Figure 28 Global Antibody Production Market Share Analysis, By Key Players, 2023
Figure 29 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
Figure 30 Merck KgaA.: Financial Overview (2023)
Figure 31 Eppendorf SE: Financial Overview (2023)
Figure 32 Agilent Technologies, Inc.: Financial Overview (2023)
Figure 33 Sartorius AG: Financial Overview (2023)
Figure 34 Danaher Corporation: Financial Overview (2023)
Figure 35 Waters Corporation: Financial Overview (2023)
Figure 36 Shimadzu Corporation: Financial Overview (2023)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Sep-2013
Published Date: Jul-2020
Published Date: Jul-2022
Published Date: Jul-2022
